Vanguard Group Inc. Raises Holdings in DexCom, Inc. $DXCM

Vanguard Group Inc. increased its position in DexCom, Inc. (NASDAQ:DXCM) by 2.3% in the 3rd quarter, Holdings Channel reports. The firm owned 49,456,043 shares of the medical device company’s stock after buying an additional 1,133,638 shares during the period. Vanguard Group Inc. owned approximately 0.13% of DexCom worth $3,327,897,000 as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in the company. Tobam increased its position in DexCom by 20.5% during the third quarter. Tobam now owns 59,948 shares of the medical device company’s stock worth $4,034,000 after buying an additional 10,193 shares during the period. Phillips Wealth Planners LLC boosted its holdings in shares of DexCom by 9.1% in the third quarter. Phillips Wealth Planners LLC now owns 3,124 shares of the medical device company’s stock valued at $207,000 after acquiring an additional 261 shares during the period. Brooktree Capital Management grew its position in shares of DexCom by 43.2% during the third quarter. Brooktree Capital Management now owns 41,880 shares of the medical device company’s stock worth $2,818,000 after acquiring an additional 12,635 shares during the last quarter. State of New Jersey Common Pension Fund D increased its holdings in shares of DexCom by 2.6% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 136,553 shares of the medical device company’s stock valued at $9,189,000 after acquiring an additional 3,425 shares during the period. Finally, Aberdeen Group plc raised its position in DexCom by 59.2% in the 3rd quarter. Aberdeen Group plc now owns 486,373 shares of the medical device company’s stock valued at $32,490,000 after purchasing an additional 180,943 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Trading Up 3.4%

Shares of DXCM stock opened at $72.80 on Thursday. The business’s fifty day moving average price is $69.30 and its 200 day moving average price is $69.35. The firm has a market capitalization of $28.02 billion, a PE ratio of 34.67, a P/E/G ratio of 1.37 and a beta of 1.49. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.88 and a quick ratio of 1.59. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $91.87.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, topping the consensus estimate of $0.65 by $0.03. The company had revenue of $1.26 billion for the quarter, compared to analyst estimates of $1.25 billion. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The business’s revenue was up 13.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.45 EPS. As a group, sell-side analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have commented on DXCM shares. Mizuho lifted their price objective on shares of DexCom from $78.00 to $90.00 and gave the company an “outperform” rating in a research note on Friday, February 13th. Leerink Partners reissued an “outperform” rating and set a $92.00 price target on shares of DexCom in a report on Tuesday, December 16th. Truist Financial reaffirmed a “buy” rating and set a $80.00 price objective (down from $82.00) on shares of DexCom in a research note on Tuesday. Weiss Ratings raised DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, February 4th. Finally, Citigroup reissued a “buy” rating and issued a $77.00 target price (up previously from $75.00) on shares of DexCom in a report on Thursday, December 11th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $85.18.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.